The aim of this study is to describe the natural history, the prognosis and the molecular analysis of a panel of cancer genes on a large series of patients with malignancy after augmentation enterocystoplasty (AE).
INTRODUCTION AND OBJECTIVES:
The aim of this study is to describe the natural history, the prognosis and the molecular analysis of a panel of cancer genes on a large series of patients with malignancy after augmentation enterocystoplasty (AE).
METHODS: A multicenter nationwide retrospective study included 16 patients based on operative, oncologic and anatomopathological reports. 11 tumor samples were analyzed using an ampliconbased Next Generation Sequencing assay specifically dedicated to the detection of clinically actionable somatic alterations of 21 relevant cancer genes.
RESULTS: AE were performed for congenital neurogenic bladders (50%) and bladder exstrophies (25%) mainly. The average age at AE was 16.5-years-old. Ileum (44%), stomach (31%), colon (19%) and ileo-colon (6%) were used for AE. The mean latency period was 20 years (5-45). Clinical manifestations, mainly hematuria, were the main circumstance of diagnosis (88%). Three patients underwent systematic endoscopy but only one was diagnosed this way. Histology showed adenocarcinomas (44%), urothelial-cell (31%), squamous-cell (19%) and undifferentiated (6%) carcinomas. 80% of gastrocystoplasties led to adenocarcinomas while urothelial-cell carcinoma was typically found after colocystoplasties. Malignancies were mainly on the bowel segment (56%) and the native bladder (43%). 75% of patients presented with an advanced stage of the disease (lymph nodes involvement: n[9 and/or distant metastasis: n[7). Urinary tract infections were statistically associated with initial metastatic status (p[0,02) but lithiasis, intermittent catheterism, immunosuppression and tumor localization were not. The 1-year overall survival rate was 50%. Only 3 patients are disease-free with a median follow-up of 70 months (10-89). Over half of analyzable samples (n[5/9) harbored missense mutations in known oncodriver genes. Two samples exhibited mutations in KIT and PDGFRA and one sample in KRAS hotspot. Two samples showed an alteration in the exon 3 of CTNNB1. One tumor that harbored a CTNNB1 mutation, also exhibits a concomitant ERBB4 alteration.
CONCLUSIONS: Malignancy after AE is lately diagnosed with frequent metastases and a very low 1-year survival rate. Systematic endoscopy is not widely used and its efficiency may be limited. We report for the first time in these tumors mutations of cancer genes for witch target therapies are available or under development. (Hsp90) is essential for the folding, stability and activity of several drivers of oncogenesis. Hsp90 inhibitors are currently under clinical evaluation in cancer patients. However, there are no biomarkers to better stratify candidate patients who would potentially respond and benefit from Hsp90 drugs. We have recently identified tumor suppressor tuberous sclerosis complex 1 (Tsc1) as a new regulator or "co-chaperone" of Hsp90 that decreases its ATPase activity. Tsc1 expression sensitizes cancer cells to Hsp90 inhibitors. Mutation of Tsc1 has been implicated in the development of bladder cancer. The objective of this work was to determine the underlying mechanism of the impact of Tsc1 on bladder cancer cell sensitivity to Hsp90 inhibitors.
METHODS: Short-interfering RNA knockdown or transient transfection of Tsc1 was used to modulate Tsc1 levels in bladder cancer cell lines. The ATP-competitive Hsp90 inhibitors ganetespib and SNX2112 were used to challenge bladder cancer cell lines. Cell proliferation was assessed by MTT assay. Apoptosis was assessed by immunoblotting.
RESULTS: Bladder cancer cell lines with wild type TSC1 (UM-UC-3, T24) were sensitive to the Hsp90 inhibitor ganetespib as evidenced by IC50 (33µM and 7µM respectively). SiRNA knockdown of TSC1 makes these cell lines resistant to Hsp90 inhibitors, with IC50s >100nM. Conversely, overexpression of wild type Tsc1-FLAG in the TSC1-null bladder cancer cell line RT4 sensitizes this cell line to apoptosis when challenged with ganetespib. Hsp90 is subject to posttranslational modifications and Hsp90 isolated from TSC1-null bladder cancer cell line RT4 appears to be hypo-acetylated compared to Tsc1-containing bladder cancer cell lines UM-UC-3 and T24.
CONCLUSIONS: Tsc1 expression appears to serve as a predictive biomarker of bladder cancer response to Hsp90 inhibitors. Additionally absence of Tsc1 leads to hypo-acetylation of Hsp90 and reduce binding to its inhibitors. Thus, HDAC inhibitors alone or in combination with Hsp90 inhibitors should be explored as a potential therapeutic approach in TSC1-null bladder cancers.
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